Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, August 26, 2026

Turmeric is good. That doesn’t mean you need supplements.

 Well, since I'm getting meals from Home Chef, it will have to be supplements. Cooking one-handed is dangerous and takes too long. 

Turmeric is good. That doesn’t mean you need supplements.

Want more stories like this? Subscribe to our menopause newsletter.

A few months ago, I was at an event when a woman came up to me with a request for this newsletter: "Will you please write about turmeric?" 

(You, too, can assign me topics to write about!)

She had seen a flurry of content on Instagram about turmeric and its anti-inflammatory properties. On account after account, women were talking about how beneficial it was for midlife and the perimenopause transition especially. They weren't just talking about cooking with the yellow spice, commonly used in Middle Eastern and South Asian cooking; they were talking about supplements. So she bought a giant bottle and started taking them — and then when she mentioned this to her doctor at her next check-up, her doctor told her to stop immediately. 

Turmeric can decrease the efficacy of tamoxifen, a drug used to prevent estrogen receptor-positive breast cancer — and one she was on. 

It's a good reminder: There are many potions and pills touted online, promising "wellness." In reality? Lots of things that seem harmless at worst and good at best can actually hurt.

So for her and the rest of us, I called up some experts to learn more about the turmeric trend. 

The science of spice

First I spoke to Dr. Nirupa Raghunathan, an internist at Memorial Sloan Kettering Cancer Center in New York. She's also an integrative medicine specialist there, so no stranger to thinking about holistic habits to support health. 

Raghunathan said as a person of South Asian heritage, she finds it fascinating to see the way a common ingredient for some cultures takes on superpower-like qualities in certain spaces. 

"Turmeric is interesting because it is a spice like almost anything else," she said. "We can attribute qualities to spices partly based on flavor, partly on what we pass down in terms of what people believe." 

Studies have shown that turmeric can have one notable anti-inflammatory benefit, specifically in regards to joint inflammation in rheumatoid arthritis. 

Preclinical research — which doesn't involve looking at effects on a full living human body — has indicated some potential benefits for the immune system, brain health and digestion. And some studies looking at large populations show that diets rich in turmeric are linked to longer lifespans. Research like this gives turmeric the sheen of being a "health food."

What happens next, Raghunathan said, is that people assume that a turmeric supplement is a natural version of ibuprofen. Except this isn't really true at all. 

Food first

There are two big differences between cooking with turmeric and taking it as a supplement: concentration and interval. 

The active component in turmeric, the one linked to anti-inflammatory effects, is the chemical curcumin. In supplements, you can't tell from a label what level of curcumin concentration there is. Some also have piperine, or black pepper oil, added to make the curcumin more absorbable and thus more potent. (It might be listed on the label as either piperine or black pepper oil; sometimes it's listed as part of a "proprietary blend.") 

On top of that, when you consume a spice you cook with, you're eating smaller amounts of it stretched over the length of time it takes to eat a full meal, whereas a supplement gives a much higher amount of the active chemicals in a quick burst. 

That's why Diane McKay, PhD, program director and assistant professor at the Friedman School of Nutrition Science and Policy at Tufts University and an expert on the role that nutrients and bioactive compounds play in healthy aging, reminds us that we already have a great way to get nutrients without buying a single bottle of pills. 

"We recommend food first," McKay said. "Try to get all of your nutrients as well as your phytonutrients and all of these other bioactive types of compounds that you find in plant-based foods and try to get them from food first because they're present with other nutrients and other compounds in the food that often optimize their intake and utilization by the body. When you isolate something and put it into a supplement, it may have a different effect."

Raghunathan said that when she speaks to patients about turmeric, she always begins by explaining that turmeric is great to use in food. 

"Have a turmeric latte if you want! Throw it into a smoothie in a reasonable dose!" 

But supplements, she said, are a whole other story. 

Curcumin is known to interact with certain liver enzymes, which means taking turmeric supplements can impact how you absorb any medication. And the piperine can have its own drug interactions. 

"If you're on multiple, complex medications, you should avoid it," Raghunathan said of turmeric supplements. 

(Great time to offer a general reminder that you should always talk to your doctor before beginning to take any kind of over-the-counter supplement!) 

Buyer beware (you're still going to age)

It's also important to remember that no supplement is going to "fix" the natural process of aging. 

Supplement manufacturers do not have to follow the same regulatory standards as pharmaceutical companies overseen by the Food and Drug Administration (FDA). Some may have pesticides and contaminants, and many are not transparent about their sourcing. 

McKay advises extra caution when it comes to buying supplements you see marketed and sold by influencers online. 

Increasingly, she said, she hears midlife influencers talking about turmeric supplements as some kind of miracle pill, a magical way to eliminate inflammation and promote longevity. This conversation is divorced from the role the actual spice holds in the culinary traditions of many cultures and also is rarely backed by any kind of substantive research. 

"It's not a general panacea," McKay said. "Healthy aging doesn't come from one of these single, hero ingredients. It comes from patterns: what we eat every day, how we move, our sleep patterns, the social connections we make." 

Raghunathan points out that Memorial Sloan Kettering Cancer Center even has its own online "About Herbs" checker, where you can research supplements to find out any potential interactions they may cause. 

"I think it's nice to think that something from nature is invariably going to be the best thing for us." But reality is more complicated than that,  Raghunathan said — something she knows even as an integrative medicine specialist herself. 

"When I have a headache, I still take an Advil. I don't go to curcumin," she said.

Concerned about inflammation? Moderate your intake of foods that are known to increase inflammation in the body — like added sugars, added saturated fat and added sodium. 

And use turmeric when it makes sense, Raghunathan said. 

"I strongly suggest if you want to include turmeric in your food, go to the spaces where culturally they've been doing it for a long time because it usually tastes better. Lentils with turmeric? It's been done in India for thousands of years, so it tastes better, probably, than trying to add turmeric in your mac and cheese."

Recombinant CXCL16 reduces brain injury by modulating microglial phenotype and attenuating apoptosis in acute ischemic stroke

 Your competent? doctor can tell you all about chemokines and their role in your recovery, right? Or are you going to say nothing and let incompetence fester? And not initiating human testing is an even worse offense!

Recombinant CXCL16 reduces brain injury by modulating microglial phenotype and attenuating apoptosis in acute ischemic stroke


Abstract

Chemokines are traditionally known for their roles in immune cell recruitment during inflammation, but emerging evidence suggests that they may also directly regulate cellular states within the central nervous system. Specifically, it remains unclear whether CXCL16 affects microglial functional states in ischemic stroke. Here, we demonstrated that recombinant CXCL16 (rCXCL16) modulated the expression of inflammation- and repair-associated markers in primary microglia and in the ischemic brain. Functionally, microglia pretreated with rCXCL16 increased HT-22 cell viability and reduced apoptosis in an indirect co-culture system. Consistently, in vivo administration of rCXCL16 reduced infarct size, restored neurobehavior performance, and suppressed apoptosis in experimental stroke in mice. These findings identify rCXCL16 as a modulator of microglial responses and suggest that its neuroprotective effects are associated with reduced inflammatory marker expression and attenuation of apoptotic injury after ischemic stroke.

Prehospital tranexamic acid in trauma and traumatic brain injury: a systematic review with meta-analysis of randomized comparative evidence

 Your competent? doctor put together a protocol on this years ago, right? NO? 

Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

Prehospital tranexamic acid in trauma and traumatic brain injury: a systematic review with meta-analysis of randomized comparative evidence

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Abstract

Background

Tranexamic acid (TXA) is commonly used in trauma care to decrease bleeding, but its effectiveness and safety in prehospital settings, notably in traumatic brain injury (TBI), remain controversial. This review aimed to systematically evaluate the evidence on prehospital tranexamic acid (TXA) use in trauma and traumatic brain injury (TBI), with quantitative meta-analysis restricted to randomized comparative evidence and non-randomized evidence summarized narratively.

Methods

We conducted a systematic review with quantitative meta-analysis restricted to independent randomized comparative studies evaluating prehospital TXA versus placebo, usual care, or no TXA. Observational studies, secondary analyses, and survey studies were summarized separately and were not pooled with randomized trials in the primary efficacy or safety meta-analysis. outcomes included mortality (28/30-day, in-hospital), thromboembolic events, seizures, and neurological consequences. Risk of bias was evaluated using Cochrane risk of bias tools for randomized controlled trials (RoB2) and non-randomized studies by Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I).

Results

Twenty-one reports met the broad review criteria. The RCT-only analysis of 28- or 30-day mortality included three independent parent randomized trials: PATCH-Trauma/Gruen et al. 2023, STAAMP/Guyette et al. 2021, and ROC-TXA/Rowell et al. 2020. Prehospital TXA was associated with lower 28- or 30-day mortality (RR 0.81, 95% CI 0.68–0.95). The TBI mortality result was derived solely from ROC-TXA/Rowell et al. 2020 and was therefore a single-study estimate rather than a pooled estimate (RR 0.87, 95% CI 0.64–1.20). In-hospital mortality was reported only by STAAMP/Guyette et al. 2021 and was also a single-study estimate (RR 0.87, 95% CI 0.57–1.33). No statistically significant increase in thromboembolic events or seizures was demonstrated. However, the DVT and PE point estimates were above the null, and their wide confidence intervals did not exclude a clinically relevant increase in thromboembolic risk.

Conclusion

Prehospital TXA may reduce 28- or 30-day mortality in selected broader trauma populations, particularly among patients at risk of hemorrhage. No statistically significant increase in thromboembolic events or seizures was demonstrated; however, clinically relevant thromboembolic harm cannot be excluded because the DVT and PE point estimates were above the null, and the confidence intervals were wide.

Study Finds Peppermint Oil May Lower Blood Pressure Within Just 20 Days

 Do nothing until your competent? doctor prescribes this in 50 years.

Study Finds Peppermint Oil May Lower Blood Pressure Within Just 20 Days

This Is What Science Says About Optimism & Your Health

 So has this longer life from pessimism been refuted then?

 I make sure I don't engage with pessimists and whiners. My optimism is extremely high, don't know how to measure it.

The latest here:

This Is What Science Says About Optimism & Your Health

Optimism is more than a mindset — new studies suggest it may tangibly improve healthspan.

The glass-half-full people might be onto something after all. Optimism is more than a worldview. There’s mounting momentum behind the idea that an optimistic outlook may be a legitimate health factor. Most recently, a study published this year in the Journal of the American Geriatrics Society contained a startling finding:

The more optimistic you are, the lower your likelihood of developing dementia in old age. Can you truly smile your way to sidestepping dementia? Maybe. But this paper is more than one point of data. The clinical case for optimism has been building for more than two decades.

What You Should Know About Optimism

Optimism is the belief that favorable outcomes are possible, that’s nothing new. It’s also not revelatory to suggest that your worldview can influence your behavior — what’s different here is the clinical backing. In fact, researchers have conducted long-term studies for decades to test the impact of optimism on real-world health outcomes.

The result? Consistent and clear: People who report higher scores on optimism scales tend to have better health outcomes across chronic disease, longevity, and mortality risk. 

Going Deeper on Optimism

Stenlund & colleagues looked at how optimism scores relate to developing dementia over a 14-year period.

  • More than 9,000 participants were assessed eight times between 2006 and 2020.
  • Every standard deviation increase in optimism was “associated with a lower hazard of developing dementia.”
  • Make no mistake: This study doesn’t say that being more optimistic cures dementia. The authors emphasized how this finding might contribute to preventative care for neurodegenerative diseases like dementia, which are particularly insidious once symptoms begin to escalate. 

While compelling, the Stenlund team’s findings aren’t the first of its kind. Several other papers have drawn links between looking on the bright side and actually living there:

  • 2004: In a 9-year study of nearly 1,000 older adults, optimists had much lower all-cause mortality — and their cardiovascular mortality risk was especially low.
  • 2009: Optimists have lower cardiovascular mortality risk.
  • 2017: High optimism is associated with a lower risk of dying from heart disease and cancer.
  • 2019: There’s a positive correlation between optimism and extended lifespan.
  • 2022: Lifestyle factors are only part of the puzzle on optimism’s tangible effects.

The Takeaway

Optimism consistently bolsters your odds of a better quality of life — tangibly, not conceptually. Studies show optimists live longer, better, and suffer fewer chronic diseases. 

It may be tempting to look at the relationship from the other side: People with an optimistic outlook are more likely to engage in health-conscious behaviors, sure. But the 2022 paper splashes cold water on that being the only reason. 

Bottom Line

There’s more going on here, but you don’t have to wait for the lab coats to figure it out to start reaping the benefits. Worth remembering: these are observational studies, so they show optimism and better health traveling together, not proof that one causes the other. But adopting an optimistic outlook is something you can start working on today, whether on your own or by taking a mindset course.

Psilocybin may make the brain more organized than scientists expected

Isn't your doctor already the competent one already prescribing psilocybin for stroke recovery? Oh NO, you DON'T have a functioning stroke doctor, do you? 

psilocybin (58 posts to May 2014) 

 Psilocybin may make the brain more organized than scientists expected

Researchers tracked psychedelic-naive adults across four very different brain-scanning environments to reveal how setting, brain dynamics and subjective experience interact during a psilocybin session.

Study: Psychedelics align brain activity with context. Image Credit: Smit / Shutterstock

A recent study published in the journal Nature investigated how psilocybin alters brain connectivity and organization across different environmental contexts.

Neural and Contextual Mechanisms of Psychedelic Action

Psychedelics are a diverse class of psychoactive substances that profoundly alter perception, mood, and cognition. They can induce striking changes in consciousness and sensory experience, including vivid visual or auditory hallucinations, a distorted sense of time, and deeply introspective or spiritual states. Compounds such as psilocybin and mescaline have a long history of use in both ceremonial and therapeutic settings. Recent research highlights their potential for lasting therapeutic effects, including reductions in depression, anxiety, and addiction, as well as enhanced social connectedness and well-being. At the neural level, psychedelics disrupt the brain’s integration of sensory input with internal models of reality. Preclinical studies indicate that psilocybin can promote structural and functional plasticity, while human imaging studies show altered communication between large-scale brain networks, leading to intensified immersion and altered self-perception. These effects are linked to more entropic, desynchronized brain dynamics, particularly within the default mode network (DMN), which is a key hub for integrating information across the brain. Psilocybin can relax connectivity patterns that normally constrain brain networks, allowing novel interactions between sensory and associative regions that may be relevant to its therapeutic effects. However, the precise mechanisms linking these neural changes to meaningful subjective experiences remain unclear.

Psychedelic outcomes are highly context-dependent, shaped by mindset and environment. However, research in this field is limited by small sample sizes, narrow imaging approaches, and studies conducted in single, artificial contexts, all of which limit generalizability. Additionally, structured tasks during brain scans may fail to capture the richness of natural psychedelic experiences. Addressing these limitations by employing larger samples, multimodal imaging, and more ecologically valid context manipulations remains a central challenge for the field.

Researchers Examined How Psychedelics Affect Brain Activity and Subjective Experience

In the open-label PsiConnect study, researchers conducted two imaging sessions: one at baseline and one after a fixed 19 mg dose of psilocybin. Each session included magnetic resonance imaging (MRI) and electroencephalography (EEG) scans across four conditions: resting state, guided meditation, music listening, and movie watching. Functional magnetic resonance imaging (fMRI) began roughly 80 minutes after dosing, following a fixed sequence to ensure safety for participants new to psychedelics. EEG sessions started after setup, beginning with the movie condition. All four conditions: resting state (eyes closed), guided meditation (audio prompts), music listening (curated playlist), and movie watching (silent clouds) were repeated at both time points.

Sixty-five participants were recruited (aged 18–55; 30 female, 35 male), stratified by age and self-reported gender, and then assigned to either an 8-week mindfulness-based intervention or a control group using a non-randomized, balanced procedure without blinding. No significant group differences emerged in the connectivity or acute subjective-effect measures examined, so data were pooled for analysis. Sample size was limited by recruitment and imaging capacity.

The fixed 19 mg dose was selected to be tolerable during imaging while producing substantial subjective effects. Behavioral and subjective measures were collected at multiple time points, with follow-up assessments extending to one year post-psilocybin.

Sixty-five healthy adults with no prior psychedelic experience producing subjective effects underwent extensive screening; three reported nominal or remote serotonergic psychedelic exposures with minimal or no recalled effects. Psilocybin administration was generally well tolerated, although three participants reported transient headaches during the night. Separately, three participants received a brief telephone follow-up from a clinical psychologist and required no further support.

Context-Driven Neural Patterns Under Psilocybin

Psilocybin reorganized brain connectivity, reducing global functional connectivity (GFC) in sensory regions and increasing it in associative regions during eyes-closed conditions. Under eyes-open conditions, GFC increased in both sensory and associative areas. These robust effects are consistent with prior research, despite individual variability.

Spatial patterns of brain signal variability shifted with context. Eyes-open movie viewing increased variability in several cortical regions, while eyes-closed conditions, especially with music, decreased variability in early visual areas. Increases were partially lateralized to the right hemisphere during eyes-closed conditions, and occipital decreases mirrored GFC patterns, a redistribution consistent with increased brain-signal entropy under psilocybin.

GFC values in the eyes-open and eyes-closed states converged under psilocybin, particularly within the visual network, with the gap shrinking by 85%. Functional modularity decreased across all conditions, largely due to reduced within-network connectivity, an effect that previous clinical studies have associated with longer-term symptom improvement. Machine learning produced low-dimensional neural representations that reliably differentiated conditions and mapped brain patterns to subjective experience.

Greater subjective-effect intensity was associated with increasingly distinct, context-specific neural organization. Stronger subjective effects produced more distinct, condition-specific neural patterns, with brain organization scaling to effect intensity.

Context-dependent neural organization was robust across dimensionality reduction methods. Classification accuracy for brain patterns peaked in those with strong self- or boundary-dissolving effects and was associated with positive next-day mindset changes. This alignment was not captured by average network segregation measures.

In a network perturbation analysis, context alignment depended most strongly on altered dynamics in both the default mode network (DMN) and the visual network. TAVRNN analysis confirmed that psilocybin produced dynamic, low-dimensional patterns reflecting evolving brain connectivity.

TAVRNN, a machine-learning model that tracks changes in brain connectivity over time, showed more cohesive organization both within individual networks and across the brain. These patterns scaled with subjective-effect intensity and were broadly preserved across contexts.

Psychedelic-naive participants reported profoundly meaningful effects, often ranking psilocybin as a top life event. Self- and boundary-dissolving experiences were common, with group-level increases in death acceptance, personal meaning, and nature relatedness measured after one month.

Anterior hippocampus–DMN effective connectivity shifted most during movie viewing, indicating that external context strongly reorganizes network interactions under psilocybin. Brief mindfulness training produced no detectable group-level differences in the acute subjective effects or connectivity measures examined, but music strongly enhanced emotional engagement and was associated with the greatest global brain organization in the TAVRNN analysis.

EEG results showed that psilocybin’s effects on brain power and complexity depend on sensory context, altering neural oscillations and signal diversity. Findings support context alignment as a cross-modal brain property.

Machine learning linked self- and boundary-dissolution to more integrated, context-aligned brain dynamics, while the authors described the corresponding subjective state as 'embeddedness': the experience of being continuous with, rather than separate from, the environment. The authors proposed embeddedness as a construct that links acute experience to subsequent psychological change, thereby supporting the temporary dissolution of internal–external boundaries.

Across measures and contexts, psilocybin reorganizes brain connectivity, redistributing sensory and associative integration in a context-dependent manner and blurring the boundary between internal and external processing. These effects are strongest with positive experiences, and a measurable neural signature is identified, associated with acute subjective experience and subsequent psychological change.

Conclusions

Psilocybin induces a dynamic reorganization of brain connectivity, characterized by context-dependent redistribution of integration across associative and sensory networks, effectively blurring the distinction between internal and external processing. This flexible neural state is most pronounced during positive, self-dissolving experiences and is reflected in both subjective reports and context-driven brain activity patterns identified by machine learning.

These findings identify a measurable neural signature linking context-sensitive brain organization with acute subjective experience and next-day mindset change, and suggest that context and subjective experience may help shape the therapeutic potential of psilocybin, although therapeutic efficacy was not tested in this healthy cohort.

Journal reference:

Cocoa looks promising for mood, but the brain benefits come with a catch

Have your competent? doctor verify an EXACT PROTOCOL on cocoa, you don't want to wait 50 years before even getting conclusive research!

 Or you could read all this research on your own and decide since your doctor won't do a damn thing!

 Cocoa looks promising for mood, but the brain benefits come with a catch

From mood regulation and gut microbes to memory and neuroplasticity, cocoa shows intriguing effects on the brain, but the strongest cognitive benefits remain largely confined to preclinical studies.

Review: Cocoa polyphenols in brain health: BDNF/CREB-mediated mechanisms in depression, cognition, and the gut–brain axis. Image Credit: InspireNest / Shutterstock

Review: Cocoa polyphenols in brain health: BDNF/CREB-mediated mechanisms in depression, cognition, and the gut–brain axis. Image Credit: InspireNest / Shutterstock

A recent study published in the journal Frontiers in Nutrition reviewed evidence on the effects of cocoa polyphenols on brain health.

Neurological and depressive disorders are significant health concerns worldwide. The pathophysiology of both depressive and neurological disorders comprises interrelated mechanisms, including excitotoxicity, mitochondrial dysfunction, and reduced expression of neurotrophic factors (e.g., brain-derived neurotrophic factor [BDNF]). Diet and nutrition have increasingly been recognized as modifiable determinants of cerebral health.

Dietary bioactive compounds, especially polyphenols, have diverse effects on the central nervous system (CNS) by acting on anti-inflammatory, neuromodulatory, and antioxidant pathways. Cocoa contains high levels of polyphenols and is recognized as a potential neuroprotective candidate. Flavanols and procyanidins are abundant in cocoa, and some cocoa-derived compounds and metabolites may reach the brain and influence cerebral regions linked to cognitive function.

Cocoa flavanols can improve cerebral blood flow and endothelial function and modulate neuroinflammation. Moreover, the flavanol epicatechin has been shown to enhance learning and spatial memory in animal models. Nevertheless, the molecular mechanisms linking cocoa polyphenols to neuroprotection have yet to be elucidated. In the present study, researchers summarized current evidence on cocoa polyphenols in the context of brain health.

Effects of cocoa polyphenols on depressive symptoms and the gut-brain axis

Clinical studies have examined the effects of dark chocolate or cocoa polyphenols on mood, emotional well-being, and depression. A randomized controlled trial in 47 overweight or obese middle-aged adults found that depressive symptoms decreased in both the cocoa and control groups after four weeks; cocoa supplementation also increased plasma homovanillic acid, which was associated with changes in depressive symptoms. Separately, another trial found modest but statistically non-significant reductions in neuropathy scores after 12-week cocoa supplementation among people with type 2 diabetes.

Further, dark chocolate intake for eight weeks was found to reduce depression among menopausal women relative to milk chocolate intake. Another study showed that consuming cocoa polyphenol beverages improved contentment and calmness after 30 days, although no significant acute effects on cognition or mood were observed. An eight-week crossover study reported that high cocoa liquor improved mood, fatigue, and residual function in individuals with chronic fatigue syndrome.

A study reported improvements in negative affect in healthy individuals with 30 g/day of 85% cocoa dark chocolate for three weeks, but not with 70% cocoa chocolate. 16S ribosomal RNA (rRNA) sequencing of fecal samples revealed an increase in gut microbial diversity and Blautia obeum levels and a reduction in Faecalibacterium prausnitzii levels. Notably, changes in negative affect negatively correlated with the relative abundance of B. obeum and microbial diversity. However, these associations did not establish that the microbiome changes caused the improvement in negative affect.

Effects of cocoa polyphenols on neural plasticity and cognitive function

Cocoa interventions have generally been reported to modulate cognitive performance and synaptic plasticity in animal models. A combination of polyunsaturated fatty acids, probiotics, and chocolate improved memory and spatial learning in Wistar rats, although the study could not isolate the contribution of chocolate. In a rat model of Alzheimer’s disease (AD), cacao administration enhanced recognition and spatial memory and decreased neuronal degeneration in the hippocampus.

Human studies have yielded more heterogeneous results. For instance, an acute dose of cocoa flavanols with or without caffeine had no effect on working memory or attention in young adults. In contrast, slight improvements in processing speed and cognitive flexibility were reported in postmenopausal women consuming 99% cocoa chocolate for six months, although other cognitive measures did not improve. However, one trial did not find improvements in reaction time and cognitive accuracy with cocoa flavanols.

Dark chocolate consumption was reported to improve verbal episodic memory in healthy young adults. Likewise, another study reported improvements in cognitive performance and increases in plasma nerve growth factor with dark chocolate. Consuming beverages high in cocoa flavanols before exercise enhanced exercise-induced improvements in executive function but did not improve memory. A four-week study found that dark chocolate intake reduced fatigue and may have indirectly enhanced cognitive performance.

Concluding remarks

Taken together, cocoa polyphenols have diverse neurocognitive health effects. The review identified the strongest evidence for effects on depression and mood, although human clinical studies remain limited and heterogeneous, and preliminary findings highlight that cocoa-induced gut microbiota changes may play a role in improving negative affect. However, their effects on cognitive domains (e.g., learning and memory) are heterogeneous. Preclinical studies report consistent improvements in hippocampal neurogenesis, spatial memory, and plasticity.

However, large randomized clinical trials have generally found negligible or no substantial improvements in overall cognition. Moreover, while preclinical studies indicate the involvement of multiple pathways underlying the reported effects, these mechanisms have not been adequately investigated in human populations. Future research should adopt more integrative, translational, and precise methodologies alongside larger, standardized, and longer-term clinical trials to better elucidate the potential therapeutic effects of cocoa polyphenols.

Journal reference:

New Research Explores How Therapy Dogs Could Support Stroke Recovery

 Your doctor is so fucking incompetent, doesn't know of this 2007 book!  

“Paws & Effect: The Healing Power of Dogs’’ (Alyson Books, 2007) 

Or this: pets (5 posts to September 2012)

New Research Explores How Therapy Dogs Could Support Stroke Recovery

Pets make everything better —  including stroke rehabilitation, a new study says.

Patients recovering from a recent stroke became more engaged in rehab sessions when a therapy animal was present, researchers report in the August edition of Mayo Clinic Proceedings.

“The presence of a therapy dog can change the entire dynamic of a rehabilitation session,” said researcher Whitney Romine. She is the manager of animal-assisted services at Mayo Clinic in Rochester, Minnesota. 

Experts discuss the challenges of living with Sickle Cell Disease and the urgent need for better healthcare advocacy and systemic change.
For the study, researchers recruited 50 recent stroke patients and randomly assigned half to undergo rehab that included visits from trained therapy dogs. The rest received standard rehab. People in the service animal group were given pet-related tasks designed to help them recuperate.

For example, patients were asked to brush the dog’s coat to build fine motor skills. They were also asked to walk a therapy dog to help relearn proper gait and posture.

Patients in the therapy animals group showed higher recovery scores. They participated more in rehab, had higher levels of physical activity, and remained mobile for longer periods.

“Stroke recovery can be challenging, particularly when patients face barriers such as low motivation or limited energy,” researcher Dr. Brent Bauer said in a news release. He is an internal medicine physician at Mayo Clinic.

“This research demonstrates that animal-assisted treatment may offer a practical and effective way to enhance engagement and support better rehabilitation outcomes,” Bauer said.

RELATED: Stroke Clinical Trials: What Black Patients Should Know Before Participating

Why Stroke Recovery Matters for Black Americans

Black Americans face a significantly higher prevalence of stroke and a higher death rate from stroke than white Americans.

Several risk factors contribute to these disparities, including:

  • High blood pressure
  • Obesity
  • Diabetes
  • Smoking
  • Chronic stress
  • Systemic racism
  • Limited access to healthy foods
  • Safe spaces for exercises

Black patients also face several disparities in acute stroke care and treatment outcomes, including delayed treatment, lower intervention rates, and higher rates of long-term disability, poorer functional recovery, and lower rates of appropriate post-acute rehabilitation or hospice referrals.

These disparities show that surviving a stroke is only part of the story. Regaining mobility, communication, independence, and quality of life also matters, but access isn’t equal across all patients.


What Could Therapy Dogs Add to Stroke Rehabilitation?

Therapy dogs aren’t meant to be seen as replacements for physical, occupational, or speech therapy for stroke survivors. Instead, researchers are studying them as a way to make rehabilitation more engaging and motivating for patients.

The new study found that patients receiving animal-assisted treatment were more engaged in rehabilitation and physically active during their inpatient stay. The findings are promising, but the study had a very small group of participants. Future research will need a much larger group of participants from diverse backgrounds to better understand therapy dogs’ impact on stroke rehabilitation.

Accessibility is also another concern. Therapy dog programs may not be available at every rehabilitation facility, leaving many patients without the opportunity to try this new approach.

RELATED: Stem Cell Therapy for Stroke Clinical Trials: What Black People Need to Know

Why Representation Matters in Stroke Research

Historically, Black Americans have been underrepresented in clinical trials, making it especially important that studies evaluating new approaches to stroke recovery include diverse participants.

A recent clinical trial involving Black men with stroke or transient ischemic attack (TIA) found that lack of awareness, transportation, phone access, and clinician referrals could all affect participation — and that community outreach, remote assessments, transportation, and involvement of healthcare providers helped address some of those barriers.

Increasing Black participation in medical research could provide more relevant findings for Black communities, and, more importantly, help improve outcomes across health conditions they are disproportionately affected by.

More information

The American Veterinary Medical Association has more on therapy animals.

SOURCE: Mayo Clinic, news release, Aug. 3, 2026